Edity

Edity Therapeutics has developed a proprietary platform for the selective delivery of intracellular proteins to diseased tissues and is developing new cellular drugs with therapeutic potential. Edity is pursuing multiple therapeutic areas and is the only company capable of targeting diseased cells with receptor-level specificity and unlocking the intracellular proteome on a large scale. The company is developing a range of candidate products in the fields of oncology, gene therapy, autoimmune diseases, and regenerative medicine.